Jaime Redondo Pedraza
17.12.25
Hypermarker aims to personalise hypertension treatment through metabolomics
Hypermarker, a European research consortium led by the University of Birmingham and funded by Horizon Europe and UK Research and Innovation (UKRI), aims to transform the way clinicians prescribe blood pressure medications by offering a more personalised, effective, and safer approach to treating hypertension.
The heart of the initiative is the Hypermarker Randomised Clinical Trial, a pan-European study designed in collaboration with patients and public bodies. The trial will explore how pharmacometabolomics (the study of how a person’s metabolism influences their response to medication) can be integrated into everyday clinical practice to tailor hypertension treatment. Machine learning algorithms will also be used to help optimise treatment decisions.
The primary objective of the trial is to develop and evaluate a personalised treatment strategy for hypertension. This approach combines patient’s clinical information with their metabolomic profile to help doctors select the most suitable class of blood pressure medication.
Participants will provide a small blood sample for metabolite testing and will receive a blood pressure device to track daily readings at home. In the study, participants will be randomised. One group will receive standard-of-care treatment. The other group will follow a personalised treatment prescribed by a doctor with access to the participant’s metabolomic profile. At the end of the study, all participants and their doctors will receive a summary of their blood pressure readings, prescribed treatments, and responses to support long-term care decisions.
Through this clinical trial, the Hypermarker consortium aims to demonstrate that combining metabolomic analysis with home-based monitoring can enhance patient adherence to medication, reduce side effects, and improve hypertension treatment. If successful, this study could pave the way for a new model of precision medicine, not only for hypertension but also for other chronic diseases.